• Genmab EPS for the quarter ending September 30, 2024 was $0.29, a 38.14% decline year-over-year.
• Genmab 2023 annual EPS was $0.96, a 19.07% decline from 2022.
• Genmab 2022 annual EPS was $1.19, a 63.45% increase from 2021.
• Genmab 2021 annual EPS was $0.73, a 34.45% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.